Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Acumen Pharmaceuticals, Inc. - Common Stock (NQ:ABOS)

2.270 +0.120 (+5.58%)

Streaming Delayed Price Updated: 3:51 PM EST, Dec 22, 2025 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	353,043
Open	2.170
Bid (Size)	2.260 (400)
Ask (Size)	2.280 (500)
Prev. Close	2.150
Today's Range	2.140 - 2.390
52wk Range	0.8551 - 2.460
Shares Outstanding	40,501,258
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Acumen Pharmaceuticals Highlights Enhanced Brain Delivery™ Technology for Oligomer-Selective Antibodies and Recruitment Strategies for Phase 2 ALTITUDE-AD Clinical Trial at 18th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference

December 02, 2025

From Acumen Pharmaceuticals, Inc.

Via GlobeNewswire

Acumen Pharmaceuticals to Present on Recruitment Strategies for Phase 2 ALTITUDE-AD Trial and Enhanced Brain Delivery Technology at 18th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference

November 18, 2025

From Acumen Pharmaceuticals, Inc.

Via GlobeNewswire

Performance

YTD	+22.7%	+22.7%
1 Month	+44.6%	+44.6%
3 Month	+77.3%	+77.3%
6 Month	+84.6%	+84.6%
1 Year	+28.2%	+28.2%

More News

Earnings Scheduled For November 12, 2025 ↗

November 12, 2025

Via Benzinga

Acumen Pharmaceuticals's Earnings: A Preview ↗

August 11, 2025

Via Benzinga

A Preview Of Acumen Pharmaceuticals's Earnings ↗

May 12, 2025

Via Benzinga

Acumen Pharmaceuticals Announces First Participant Dosed in Phase 2 Open-Label Extension Study of Sabirnetug in People with Early Alzheimer’s Disease

November 17, 2025

From Acumen Pharmaceuticals, Inc.

Via GlobeNewswire

Acumen Pharmaceuticals Inc (NASDAQ:ABOS) Reports Q3 2025 Earnings, Beats EPS Estimates ↗

November 12, 2025

Via Chartmill

Acumen Pharmaceuticals Reports Third Quarter 2025 Financial Results and Business Highlights

November 12, 2025

From Acumen Pharmaceuticals, Inc.

Via GlobeNewswire

Preview: Acumen Pharmaceuticals's Earnings ↗

November 11, 2025

Via Benzinga

Acumen Pharmaceuticals Appoints George Golumbeski, Ph.D., as Chairman of its Board of Directors

November 10, 2025

From Acumen Pharmaceuticals, Inc.

Via GlobeNewswire

Acumen Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 12, 2025

November 05, 2025

From Acumen Pharmaceuticals, Inc.

Via GlobeNewswire

Acumen Pharmaceuticals to Participate in the Stifel Healthcare Conference

November 04, 2025

From Acumen Pharmaceuticals, Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

September 25, 2025

Via Benzinga

Acumen Pharmaceuticals to Participate in Upcoming Investor Conferences

August 26, 2025

From Acumen Pharmaceuticals, Inc.

Via GlobeNewswire

Acumen Pharmaceuticals Reports Second Quarter 2025 Financial Results and Business Highlights

August 12, 2025

From Acumen Pharmaceuticals, Inc.

Via GlobeNewswire

Acumen Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 12, 2025

August 05, 2025

From Acumen Pharmaceuticals, Inc.

Via GlobeNewswire

Acumen Pharmaceuticals Presents Studies Showing the Utility of a pTau217 Assay in Screening for a Phase 2 Alzheimer’s Disease Trial and Validates Sabirnetug Oligomer-Selectivity, at the Alzheimer’s Association International Conference (AAIC) 2025

July 28, 2025

From Acumen Pharmaceuticals, Inc.

Via GlobeNewswire

Earnings Scheduled For August 12, 2025 ↗

August 12, 2025

Via Benzinga

Acumen Pharmaceuticals and JCR Pharmaceuticals Enter Strategic Collaboration, Option and License Agreement to Develop Enhanced Brain Delivery™ Therapy for Alzheimer’s Disease

July 15, 2025

From Acumen Pharmaceuticals, Inc.

Via GlobeNewswire

Acumen Pharmaceuticals to Present Studies on Cost Savings Associated with Use of pTau217 Screening Assay in Phase 2 ALTITUDE-AD Study and Sabirnetug Oligomer-Selectivity at the Alzheimer’s Association International Conference (AAIC®) 2025

July 10, 2025

From Acumen Pharmaceuticals, Inc.

Via GlobeNewswire

Acumen Pharmaceuticals Reports First Quarter 2025 Financial Results and Business Highlights

May 13, 2025

From Acumen Pharmaceuticals, Inc.

Via GlobeNewswire

Acumen Pharmaceuticals to Participate in the Bank of America Healthcare Conference

May 07, 2025

From Acumen Pharmaceuticals, Inc.

Via GlobeNewswire

Acumen Pharmaceuticals to Report First Quarter 2025 Financial Results on May 13, 2025

May 06, 2025

From Acumen Pharmaceuticals, Inc.

Via GlobeNewswire

Earnings Scheduled For May 13, 2025 ↗

May 13, 2025

Via Benzinga

Acumen Pharmaceuticals Showcases pTau217 Trial Screening Progress in Phase 2 ALTITUDE-AD Trial and Preclinical Research Methods at AD/PD 2025 and AAN Annual Meeting

April 02, 2025

From Acumen Pharmaceuticals, Inc.

Via GlobeNewswire

Frequently Asked Questions

Is Acumen Pharmaceuticals, Inc. - Common Stock publicly traded?

Yes, Acumen Pharmaceuticals, Inc. - Common Stock is publicly traded.

What exchange does Acumen Pharmaceuticals, Inc. - Common Stock trade on?

Acumen Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Acumen Pharmaceuticals, Inc. - Common Stock?

The ticker symbol for Acumen Pharmaceuticals, Inc. - Common Stock is ABOS on the Nasdaq Stock Market

What is the current price of Acumen Pharmaceuticals, Inc. - Common Stock?

The current price of Acumen Pharmaceuticals, Inc. - Common Stock is 2.270

When was Acumen Pharmaceuticals, Inc. - Common Stock last traded?

The last trade of Acumen Pharmaceuticals, Inc. - Common Stock was at 12/22/25 03:51 PM ET

What is the market capitalization of Acumen Pharmaceuticals, Inc. - Common Stock?

The market capitalization of Acumen Pharmaceuticals, Inc. - Common Stock is 91.94M

How many shares of Acumen Pharmaceuticals, Inc. - Common Stock are outstanding?

Acumen Pharmaceuticals, Inc. - Common Stock has 92M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.